[HTML][HTML] Factors affecting the harmonization of disease-related metabolic brain pattern expression quantification in [18F] FDG-PET (PETMETPAT)
RV Kogan, BA de Jong, RJ Renken, SK Meles… - Alzheimer's & Dementia …, 2019 - Elsevier
Introduction The implementation of spatial-covariance [18 F] fluorodeoxyglucose positron
emission tomography–based disease-related metabolic brain patterns as biomarkers has …
emission tomography–based disease-related metabolic brain patterns as biomarkers has …
The effect of 18F-FDG-PET image reconstruction algorithms on the expression of characteristic metabolic brain network in Parkinson's disease
P Tomše, L Jensterle, S Rep, M Grmek, K Zaletel… - Physica medica, 2017 - Elsevier
Purpose To evaluate the reproducibility of the expression of Parkinson's Disease Related
Pattern (PDRP) across multiple sets of 18F-FDG-PET brain images reconstructed with …
Pattern (PDRP) across multiple sets of 18F-FDG-PET brain images reconstructed with …
Single-subject SPM FDG-PET patterns predict risk of dementia progression in Parkinson disease
Objective To evaluate the statistical parametric mapping (SPM) procedure for
fluorodeoxyglucose (FDG)-PET imaging as a possible single-subject marker of progression …
fluorodeoxyglucose (FDG)-PET imaging as a possible single-subject marker of progression …
[PDF][PDF] Differentiating between normal aging, mild cognitive impairment, and Alzheimer's disease with FDG-PET: Effects of normalization region and partial volume …
Abstract Objective: In Alzheimer's FDG PET research, the choice of reference region for
normalization and use of partial volume correction are inconsistent and have not been …
normalization and use of partial volume correction are inconsistent and have not been …
A Standardized [18F]-FDG-PET Template for Spatial Normalization in Statistical Parametric Mapping of Dementia
PA Della Rosa, C Cerami, F Gallivanone, A Prestia… - Neuroinformatics, 2014 - Springer
Abstract [18 F]-fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) is a widely
used diagnostic tool that can detect and quantify pathophysiology, as assessed through …
used diagnostic tool that can detect and quantify pathophysiology, as assessed through …
[HTML][HTML] Atypical brain FDG-PET patterns increase the risk of long-term cognitive and motor progression in Parkinson's disease
Introduction Brain hypometabolism patterns have been previously associated with cognitive
decline in Parkinson's disease (PD). Our aim is to evaluate the impact of single-subject …
decline in Parkinson's disease (PD). Our aim is to evaluate the impact of single-subject …
Abnormal metabolic brain network associated with Parkinson's disease: replication on a new European sample
P Tomše, L Jensterle, M Grmek, K Zaletel, Z Pirtošek… - Neuroradiology, 2017 - Springer
Purpose The purpose of this study was to identify the specific metabolic brain pattern
characteristic for Parkinson's disease (PD): Parkinson's disease-related pattern (PDRP) …
characteristic for Parkinson's disease (PD): Parkinson's disease-related pattern (PDRP) …
Validation of 18F–FDG-PET Single-Subject Optimized SPM Procedure with Different PET Scanners
Abstract 18 F–fluoro-deoxy-glucose Positron Emission Tomography (FDG-PET) allows early
identification of neurodegeneration in dementia. The use of an optimized method based on …
identification of neurodegeneration in dementia. The use of an optimized method based on …
A zero-dose synthetic baseline for the personalized analysis of [18F]FDG-PET: Application in Alzheimer's disease
C Hinge, OM Henriksen, U Lindberg… - Frontiers in …, 2022 - frontiersin.org
Purpose Brain 2-Deoxy-2-[18F] fluoroglucose ([18F] FDG-PET) is widely used in the
diagnostic workup of Alzheimer's disease (AD). Current tools for uptake analysis rely on non …
diagnostic workup of Alzheimer's disease (AD). Current tools for uptake analysis rely on non …
[HTML][HTML] FDG PET Parkinson's disease-related pattern as a biomarker for clinical trials in early stage disease
DC Matthews, H Lerman, A Lukic, RD Andrews… - NeuroImage: Clinical, 2018 - Elsevier
Background The development of therapeutic interventions for Parkinson disease (PD) is
challenged by disease complexity and subjectivity of symptom evaluation. A Parkinson's …
challenged by disease complexity and subjectivity of symptom evaluation. A Parkinson's …